Imatinib
Back to searchMolecule Structure
Scientific Name
Imatinib
Description of the Drug
Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00619
http://www.drugbank.ca/drugs/DB00619
Brand Name(s)
Not Available
Company Owner(s)
Apotex Inc, Wockhardt Bio Ag, Amneal Pharmaceuticals Of New York Llc, Sun Pharmaceutical Industries Ltd, Shilpa Medicare Ltd, Natco Pharma Ltd, Eugia Pharma Specialities Ltd, Dr Reddys Laboratories Ltd, Teva Pharmaceuticals Usa, Mylan Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase ABL | SINGLE PROTEIN | INHIBITOR | CHEMBL1862 |
| Platelet-derived growth factor receptor beta | SINGLE PROTEIN | INHIBITOR | CHEMBL1913 |
| Bcr/Abl fusion protein | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2096618 |
| Stem cell growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1936 |
Clinical Trial(s)
Unichem Links
| Atlas | imatinib | |||
| SureChEMBL | SCHEMBL3827 | |||
| PharmGKB | PA10804 | |||
| Human Metabolome Database | HMDB0014757 | |||
| DrugBank | DB00619 | |||
| PubChem: Thomson Pharma | 14859628 | |||
| PubChem | 5291 | |||
| Mcule | MCULE-2384256888 | |||
| LINCS | LSM-1023 | |||
| Nikkaji | J1.337.143A | |||
| PDBe | STI | |||
| BindingDB | 13530 | |||
| EPA CompTox Dashboard | DTXSID3037125 | |||
| DrugCentral | 1423 | |||
| Brenda | 163324 | 229530 | 229529 | 2314 |
| ChemicalBook | CB7370890 | |||
| Guide to Pharmacology | 5687 | |||
| rxnorm | IMATINIB MESYLATE | GLEEVEC | IMATINIB | |
| ChEBI | 45783 | |||
| ZINC | ZINC000019632618 |
